인간배아줄기세포의 특허보호에 관한 유럽의 최신 동향 - 유럽사법재판소의 Brüstle v. Greenpeace 판결을 중심으로 -
Recent Tendency on the Patent Protection of Human Embryonic Stem Cells in Europe - based upon Brüstle v. Greenpeace case of European Court of Justice -
The researches on human embryonic stem cells(hESC) which are carried out by many developed countries in this area including the U.S., west european countries, Japan etc. are aiming for treatment of neural diseases such as Alzheimer's disease, cancer. However, patent protection on hESC brings an issue on bioethics, in which the matter is from which stage of development after fertilization embryo is regarded as a human being, because it generally originates from destruction of human embryo if stem cells are derived from the embryo. The Directive 98/44/EC on legal protection of biotechnological invention as to including matters on biotechnological inventions in Europe does not have any definition on what is ‘human embryo’. Therefore, there have been many disputes on the correct meaning of what is embryo as well as what is use of human embryos for industrial or commercial purposes according to Rule 28 of Implementing Regulation to the EPC(European Patent Convention). In this regard, the Brstle v. Greenpeace case of European Court of Justice in 2012 has an important meaning. This case shows what is embryo, which is broadly interpreted than ever. Following the purpose of this case, the UK Intellectual Property Office has revised the Practice Notices in 2012, and published the Examination Guidelines for Patent Applications relating to Biotechnological Inventions in 2013. In addition, German Federal Supreme Court has made a decision on Brüstle case in 2012, in which the human embryo appears to be interpreted narrower than the ECJ. In the future, it is anxious how both ECJ’s judgment and German Federal Supreme Court(BGH)’s judgment on Brüstle case are influenced upon European Patent Office as well as other european countries’ courts. It is meaningful for us to compare and analyze the interpretations of ECJ and BGH on patentability of human embryonic stem cells in Europe.
목차
I. 들어가며 II. EU 바이오지침에서 인간배아줄기세포의 특허보호 1. 서 2. 인간배아와 관련된 EU 바이오지침 3. 유럽윤리위원회(EGE)의 견해 III. 유럽사법재판소의 판결 - Brüstle v.Greenpeace 사건(C-34/10) 1. 사건 개요 2. 유럽사법재판소의 판결 및 분석 3. 유럽특허청의 확대항고부 사건(G 2/06)과의 관계 IV. 유럽사법재판소 판결(C 34/10) 후 각국의 동향 1. 독일 2. 영국 3. 프랑스 V. 맺으며 참고문헌
본 학회는 지식재산 및 관련 제도(특허, 실용신안, 상표, 디자인, 영업비밀, 저작권, 반도체칩, 컴퓨터프로그램, 데이터베이스, 디지털콘텐츠 등)에 관한 국내외 이론과 실무에 대한 연구를 촉진하여 지식재산분야의 학문간 융합발전과 국제적 유대를 강화하고, 지식재산에 관한 지식을 보급하여 인적 네트워크 구축과 정책제언을 추진하며 이를 통해 국가발전에 이바지하는 것을 목적으로 한다.